CA2166320A1 - Derives d'ansamycine, agents antioncogenes et anticancers - Google Patents

Derives d'ansamycine, agents antioncogenes et anticancers

Info

Publication number
CA2166320A1
CA2166320A1 CA002166320A CA2166320A CA2166320A1 CA 2166320 A1 CA2166320 A1 CA 2166320A1 CA 002166320 A CA002166320 A CA 002166320A CA 2166320 A CA2166320 A CA 2166320A CA 2166320 A1 CA2166320 A1 CA 2166320A1
Authority
CA
Canada
Prior art keywords
alkyl
demethoxygeldanamycin
group
amino
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002166320A
Other languages
English (en)
Inventor
Randall James Gallaschun
Mikel Paul Moyer
Rodney Caughren Schnur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2166320A1 publication Critical patent/CA2166320A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte à un composé de formule (I) dans laquelle R<1>, R<2>, R<3>, R<4>, R<5> et R<6> ont la définition figurant dans la définition, ainsi qu'à ses sels et promédicaments pharmaceutiquement acceptables; l'invention se rapporte également aux procédés et produits intermédiaires servant à la préparation dudit composé, à ses compositions pharmaceutiques et aux méthodes de traitement l'utilisant. Les composés de formule (I) sont utiles pour l'inhibition des produits d'oncogènes ainsi qu'en tant qu'agents antitumoraux et anticancéreux.
CA002166320A 1993-06-29 1994-06-16 Derives d'ansamycine, agents antioncogenes et anticancers Abandoned CA2166320A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8506593A 1993-06-29 1993-06-29
US08/085,065 1993-06-29

Publications (1)

Publication Number Publication Date
CA2166320A1 true CA2166320A1 (fr) 1995-01-12

Family

ID=22189242

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002166320A Abandoned CA2166320A1 (fr) 1993-06-29 1994-06-16 Derives d'ansamycine, agents antioncogenes et anticancers

Country Status (5)

Country Link
EP (1) EP0706516A1 (fr)
JP (1) JP2794342B2 (fr)
CA (1) CA2166320A1 (fr)
FI (1) FI943100A (fr)
WO (1) WO1995001342A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1098666B1 (fr) 1998-07-17 2013-01-16 The United States of America, represented by the Secretary, Department of Health and Human Services Medicaments solubles a l'eau et procedes de preparation de ceux-ci
JP2002541255A (ja) * 1999-04-09 2002-12-03 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｅｒ族チロシンキナーゼの分解および／または阻害方法および組成物
AU2002217866A1 (en) * 2000-11-06 2002-05-15 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Geldanamycin derivatives useful for the treatment of cancer
ATE334119T1 (de) * 2001-03-30 2006-08-15 Us Health Geldanamycinderivate zur krebsbehandlung
EP1420747A4 (fr) * 2001-08-06 2010-06-02 Kosan Biosciences Inc Ansamycine benzoquinone
CA2460498A1 (fr) * 2001-09-24 2003-04-03 Conforma Therapeutics Corporation Procede de preparation de 17-allyl amino geldanamycine (17-aag) et d'autres ansamycines
EP1923061A1 (fr) 2001-09-24 2008-05-21 Conforma Therapeutic Corporation Procédé pour la préparation de 17-allyl amino geldanamycine (17-AAG) et autres ansamycines
AU2003217393B8 (en) 2002-02-08 2009-06-25 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
EP1605931A4 (fr) * 2003-03-13 2009-04-29 Conforma Therapeutics Corp Preparations medicamenteuses contenant des triglycerides a longue chaine et a chaine moyenne
US6870049B1 (en) 2003-11-12 2005-03-22 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6855705B1 (en) 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6875863B1 (en) 2003-11-12 2005-04-05 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
DK1716119T3 (da) 2003-12-23 2013-06-10 Infinity Discovery Inc Analoger af benzoquinonholdige ansamyciner til behandling af cancer
US20060019941A1 (en) * 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
CN102245021B (zh) 2008-10-15 2014-09-17 无限药品公司 安莎霉素氢醌组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3595955A (en) * 1969-03-26 1971-07-27 Upjohn Co Geldanamycin and process for producing same
US3987035A (en) * 1974-04-05 1976-10-19 University Of Illinois Foundation Biologically active compounds
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
CA2127457A1 (fr) * 1992-01-06 1993-07-22 Walter P. Cullen Methode de preparation et utilisations de 4,5-dihydrogeldanamycine et de son hydroquinone

Also Published As

Publication number Publication date
WO1995001342A1 (fr) 1995-01-12
EP0706516A1 (fr) 1996-04-17
FI943100A0 (fi) 1994-06-28
JP2794342B2 (ja) 1998-09-03
JPH08506356A (ja) 1996-07-09
FI943100A (fi) 1994-12-30

Similar Documents

Publication Publication Date Title
US5932566A (en) Ansamycin derivatives as antioncogene and anticancer agents
CA2166320A1 (fr) Derives d&#39;ansamycine, agents antioncogenes et anticancers
US4923986A (en) Derivatives of physiologically active substance K-252
US9163060B2 (en) Tubulin inhibitors
US5084468A (en) Dc-88a derivatives
KR100616039B1 (ko) 비피페리디닐-유도체 및 이의 케모킨 수용체 억제제로서의 용도
US20060205719A1 (en) Novel compounds having an antibacterial activity
JP2009516735A (ja) 新規チオフェン誘導体
CZ289787A3 (cs) Substituovaný benzamidový derivát, způsob jeho výroby a farmaceutický prostředek na jeho bázi
AU2009200606A1 (en) Novel oxazolidinone derivatives
US5656648A (en) Polysubstituted 2-amino-thiazole derivatives
KR0164599B1 (ko) 피리다진 유도체 이의 제조방법 및 이것을 함유하는 약학 조성물
JP3009465B2 (ja) ６，９−ビス（置換アミノ）ベンゾ〔ｇ〕イソキノリン−５，１０−ジオン類
EP0009655B1 (fr) N-pyrrolyl-3-pyridazine-amines substituées par un groupe amine en position 6, leur préparation et compositions pharmaceutiques à activité anti-hypertensive contenant lesdits composés
JPH05247055A (ja) スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
US4247551A (en) N-Pyrrolyl-pyridazineamines and their use as antihypertensive agents
US4835160A (en) Derivatives of pyridoindole, having anti-tumor properties
NO309603B1 (no) Fremgangsmåte til fremstilling av substituerte dibenz[b,f][1,4]-oksazepin-11(10H)oner
WO2003072574A1 (fr) Piperidine ouracile en tant que medicament pour traiter des infections bacteriennes
HU223948B1 (hu) Metotrexát-származékok, ilyeneket tartalmazó gyógyszerkészítmények és eljárás előállításukra
KR920007497B1 (ko) Lo/co 억제 벤즈옥사졸론
EP0529395A2 (fr) Benzamides comme agents pour supprimer la résistance à de multiples médicaments
US5374711A (en) Chemical modification of 2&#34;-amino group in elsamicin a
RU2183626C2 (ru) Производные фенантридиния, фармацевтическая композиция, обладающая противоопухолевой активностью, способ ингибирования роста раковых клеток
WO2005035528A2 (fr) Nouveaux composes triazoliques, leur procede de preparation et compositions pharmaceutiques les contenant

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead